A categorical structure-activity relationship analysis of the developmental toxicity of antithyroid drugs.

International Journal of Pediatric Endocrinology
A R CunninghamDonald R Mattison

Abstract

The choice of therapeutic strategies for hyperthyroidism during pregnancy is limited. Surgery and radioiodine are typically avoided, leaving propylthiouracil and methimazole in the US. Carbimazole, a metabolic precursor of methimazole, is available in some countries outside of the US. In the US propylthiouracil is recommended because of concern about developmental toxicity from methimazole and carbimazole. Despite this recommendation, the data on developmental toxicity of all three agents are extremely limited and insufficient to support a policy given the broad use of methimazole and carbimazole around the world. In the absence of new human or animal data we describe the development of a new structure-activity relationship (SAR) model for developmental toxicity using the cat-SAR expert system. The SAR model was developed from data for 323 compounds evaluated for human developmental toxicity with 130 categorized as developmental toxicants and 193 as nontoxicants. Model cross-validation yielded a concordance between observed and predicted results between 79% to 81%. Based on this model, propylthiouracil, methimazole, and carbimazole were observed to share some structural features relating to human developmental toxicity. Thus gi...Continue Reading

References

Jun 1, 1984·Clinical Endocrinology·N MomotaniT Mimura
Jul 1, 1994·Prenatal Diagnosis·M R Verschraegen-Spae, A De Paepe
Aug 1, 1994·Risk Analysis : an Official Publication of the Society for Risk Analysis·N TakihiD R Mattison
Apr 1, 1997·American Journal of Obstetrics and Gynecology·M GhanooniG Klopman
Nov 14, 1997·The Journal of Clinical Endocrinology and Metabolism·N MomotaniK Ito
Oct 6, 1999·Teratology·J GómezH S Rosenkranz
Jun 9, 2001·The Journal of Clinical Endocrinology and Metabolism·S J Mandel, D S Cooper
May 23, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Grace W Chan, Susan J Mandel
Oct 20, 2007·The Journal of Clinical Endocrinology and Metabolism·Marcos AbalovichAlex Stagnaro-Green
Mar 22, 2008·BMJ : British Medical Journal·Helen MarxJohn H Lazarus
Aug 2, 2008·Birth Defects Research. Part A, Clinical and Molecular Teratology·Lakshminarayanan KannanMadhulika Kabra
Aug 14, 2008·American Journal of Medical Genetics. Part a·Pablo BarberoRosa Liascovich
Aug 20, 2008·Expert Opinion on Pharmacotherapy·Onyebuchi E OkosiemeJohn H Lazarus
Sep 2, 2008·Chemical Research in Toxicology·Albert R CunninghamSuzanne L Cunningham
Feb 14, 2009·Birth Defects Research. Part A, Clinical and Molecular Teratology·Marilyn L BrowneUNKNOWN National Birth Defects Prevention Study
Dec 1, 2009·International Journal of Pediatric Endocrinology·Scott A Rivkees, Donald R Mattison
Dec 22, 2009·SAR and QSAR in Environmental Research·M Bolcic-Tavcar, M Vracko

❮ Previous
Next ❯

Citations

Apr 25, 2012·PloS One·Valeria C BenavidesScott A Rivkees

❮ Previous
Next ❯

Software Mentioned

MultiCASE
Cat
HQSAR
TERIS
Tripos
MOL2
SAR

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

The Journal of Clinical Endocrinology and Metabolism
Hirotoshi NakamuraNoboru Hamada
Brazilian Journal of Otorhinolaryngology
Roberta Werlang Isolan-CuryAlexandre Iglesias
© 2021 Meta ULC. All rights reserved